Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis.
Worldwide cannabis dependence is increasing, as is the concentration of Delta(9)-tetrahydrocannabinol (THC) in street cannabis. At the same time, the concentration of the second most abundant cannabinoid in street cannabis, cannabidiol (CBD), is decreasing. These two cannabinoids have opposing effects both pharmacologically and behaviorally when administered in the laboratory. No research has yet examined how the ratio of these constituents impacts on the appetitive/reinforcing effects of cannabis in humans. A total of 94 cannabis users were tested 7 days apart, once while non-intoxicated and once while acutely under the influence of their own chosen smoked cannabis on dependence-related measures. Using an unprecedented methodology, a sample of cannabis (as well as saliva) was collected from each user and analyzed for levels of cannabinoids. On the basis of CBD : THC ratios in the cannabis, individuals from the top and bottom tertiles were directly compared on indices of the reinforcing effects of drugs, explicit liking, and implicit attentional bias to drug stimuli. When intoxicated, smokers of high CBD : THC strains showed reduced attentional bias to drug and food stimuli compared with smokers of low CBD : THC. Those smoking higher CBD : THC strains also showed lower self-rated liking of cannabis stimuli on both test days. Our findings suggest that CBD has potential as a treatment for cannabis dependence. The acute modulation of the incentive salience of drug cues by CBD may possibly generalize to a treatment for other addictive disorders.
Morgan
Celia J A
CJ
Clinical Psychopharmacology Unit, Research Department of Clinical, Health and Educational Psychology, University College London, London, UK. c.morgan@ucl.ac.uk
Freeman
Tom P
TP
Schafer
Gráinne L
GL
Curran
H Valerie
HV
D000293:Adolescent; D000704:Analysis of Variance; D001070:Appetitive Behavior / Q000187:drug effects*; D002185:Cannabidiol / Q000008:administration & dosage / Q000627:therapeutic use* / Q000652:urine; D002755:Choice Behavior / Q000187:drug effects; D002853:Chromatography, Liquid / Q000379:methods; D013759:Dronabinol / Q000008:administration & dosage* / Q000652:urine; D005260:Female; D006213:Hallucinogens / Q000008:administration & dosage* / Q000652:urine; D006801:Humans; D008297:Male; D002189:Marijuana Abuse; D008385:Marijuana Smoking / Q000188:drug therapy* / Q000523:psychology* / Q000652:urine; D013058:Mass Spectrometry / Q000379:methods; D009483:Neuropsychological Tests; D011930:Reaction Time / Q000187:drug effects; D055815:Young Adult
D006213:Hallucinogens; D002185:Cannabidiol; D013759:Dronabinol